

**ROXADUSTAT tablets (Evrenzo® ▼)
for treatment of anaemia associated with chronic kidney disease**

**The Pan Mersey Area Prescribing Committee does not currently recommend
the prescribing of ROXADUSTAT tablets (Evrenzo® ▼)
for treatment of anaemia associated with chronic kidney disease.**

GREY

Roxadustat is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD).^[1]

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, treatment of anaemia associated with CKD should continue to follow national guidance, local pathways and local formulary choices:

- > NICE Guideline [NG203]: [Chronic kidney disease: assessment and management](#) (25 August 2021)
- > NICE Pathway: [Chronic kidney disease](#) (updated 25 August 2021)
- > NICE Clinical Knowledge Summary: [Chronic kidney disease](#) (update August 2021)
- > Pan Mersey APC Formulary: [Nutrition and blood](#)

References

1. Astellas Pharma Ltd. Summary of Product Characteristics; [Evrenzo \(roxadustat\) film coated tablets](#), 27 August 2021. Accessed online 14 October 2021.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.